key: cord-0901695-dew27tbp authors: Meir, Juliet; Abid, Muhammad Abbas; Abid, Muhammad Bilal title: STATE OF THE CAR-T: Risk of Infections with CAR-T Therapy and Determinants of SARS-CoV-2 Vaccine Responses date: 2021-09-27 journal: Transplant Cell Ther DOI: 10.1016/j.jtct.2021.09.016 sha: 68721d0d2b31f14f9cbda09e618eecdd2557b915 doc_id: 901695 cord_uid: dew27tbp Chimeric antigen receptor T-cell (CAR-T) therapy has shown unprecedented response rates in patients with relapsed/refractory (R/R) hematological malignancies. While CAR-T therapy renders hope to heavily pre-treated patients, the rapid commercialization and cumulative immunosuppression predispose patients to infections for a prolonged period. CAR-T poses distinctive short- and long-term toxicities and infection risks among patients who receive CAR-T after multiple prior treatments, often including hematopoietic cell transplantation. The acute toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The long-term B-cell depletion, hypogammaglobulinemia, and cytopenia further predispose patients to severe infections and abrogate the remission success achieved by the living drug. These on-target-off-tumor toxicities deplete B-cells across the entire lineage and further diminish immune responses to vaccines. Early observational data suggest that patients with hematologic malignancies may not mount an adequate humoral and cellular response to SARS-CoV-2 vaccines. In this review, we summarize the immune comprising factors indigenous to CAR-T recipients. We discuss the immunogenic potential of different SARS-CoV-2 vaccines based on the differences in the manufacturing platforms among CAR-T recipients. Given the lack of data related to the safety and efficacy of SARS-CoV-2 vaccines in this distinctively immunosuppressed cohort, we summarize the infection risks associated with FDA-approved CAR-T constructs and the potential determinants of vaccine responses. The review further highlights the potential need for booster vaccine dosing and the promise for heterologous prime-boosting in CAR-T recipients. 4. Due to differential expression patterns on the B-cell surface, CAR-T targeting CD19 likely results in more bacterial infections, whereas viral infections commonly occur following anti-BCMA CAR-T. 5 . Data related to COVID-19 outcomes and vaccine responses among CAR-T recipients is evolving and suggests that vaccine responses among CAR-T recipients may even be more diminished than allogeneic HCT recipients. 6 . In addition to concerns related to suboptimal efficacy, CAR-T recipients could theoretically experience a heightened risk of immune-mediated toxicity. There are no anti-SARS-CoV-2 spike binding (anti-S IgG) and neutralizing antibody titers validated among immunocompromised patients. Further, inter-assay variability and the level of humoral response that correlates with clinical protection remains unknown. 8 . While the FDA advises against checking vaccine responses, routine serological assessment to gauge vaccine responses could be considered in select CAR-T recipients to determine the number of additional vaccine doses. However, CAR-T recipients should be advised to continue the strict precautionary behavior irrespective of the immune responses. 9 . Telemedicine should be incorporated at the core of long term follow up to minimize exposure of immunosuppressed patients to the hospitals and the community. 10 . The timing and intensity of corticosteroid usage, both for the prevention and treatment of CAR-T toxicities, should be evaluated in the context of potentially diminished immune responses to SARS-CoV-2 vaccines. 11 . Given the immunosuppressed milieu as a driver for mutational SARS-CoV-2 variants, antiviral agents and long-acting monoclonal antibodies or small molecules, potentially resistant to current SARS-CoV-2 mutations, need evaluation in prospective studies to halt the development of mutations and spread to close contacts. 12 . The risk of transmission should be minimized by vaccinating all healthcare workers and caregivers, and strict mitigation strategies should remain across transplantation and cellular therapy centers. Chimeric antigen receptor T-cell (CAR-T) therapy has shown unprecedented response rates in patients with relapsed/refractory (R/R) hematological malignancies. While CAR-T therapy renders hope to heavily pre-treated patients, the rapid commercialization and cumulative immunosuppression predispose As of this writing, the US Food and Drug Administration (FDA) has approved several CAR-T constructs directed against CD19 and B-cell maturation antigen (BCMA). These include tisagenlecleucel (tisacel/Kymriah) for the treatment of R/R acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), axicabtagene ciloleucel (axi-cel/Yescarta) and lisocabtagene maraleucel (lisocel/Breyanzi) for the treatment of R/R DLBCL and other lymphomas that share similar histopathological features, and brexucabtagene autoleucel (Brex-cel / Tecartus) for R/R mantle cell lymphoma (MCL). More recently, idecabtagene vicleucel (ide-cel / Abecma) -directed against BCMA -has been FDAapproved for the treatment of RRMM [4] [5] [6] [7] [8] [9] . Although CAR-T prolongs the survival of patients with relapsed and refractory diseases, the associated on-target off-tumor toxicities, particularly infections, limit the effective utilization of this curative therapy. CAR-T poses distinctive short-and long-term toxicities and infection risks among patients who receive CAR-T after multiple prior treatments, often including hematopoietic cell transplantation (HCT). CAR-T construct, signaling domains, cytokine release syndrome (CRS), neurotoxicity, and peri-CAR-T interventions confer risk of unique infections in the early period. The long-term B-cell depletion, hypogammaglobulinemia, and cytopenia further predispose patients to severe infections and abrogate the remission success achieved by the living drug. The infection-related data reported thus far is limited to CD19-targeted CAR-T. In a single-center retrospective study, examining 85 axi-cel recipients with LBCL who maintained remission post-CAR-T, 37% of patients developed infections by day+30 of which 13% were severe. Severe infections were associated with CRS, neurotoxicity, tocilizumab and corticosteroid use, and bridging therapy on univariate analysis 10 . A greater body of clinical data are summarized in the section VIII below. As of August 1, 2021, SARS-CoV-2 has infected more than 200 million people and caused more than 4 million deaths globally. Patients with cancers are at a particularly higher risk, and those with HMs are at the highest risk of severe COVID-19 and mortality (13-39%) 11, 12, 13, [14] [15] [16] [17] . The HCT and CAR-T recipients are at an even higher risk 18 The study from New York also included 5 CAR-T patients who had received CAR-T products directed against CD19. All had B-cell non-Hodgkin's lymphoma (B-NHL), and 4 of 5 CAR-T recipients had received axi-cel whereas 1 received tisa-cel 16 . In another case report, a 73-year-old patient with relapsed/refractory multiple myeloma (RRMM) developed severe COVID-19 twelve days after receiving CAR-T targeting BCMA. The patient developed persistent viremia that lasted more than 2 months. The patient eventually died, and postmortem sequencing revealed viral evolution with multiple sequence variants within the host concurrent with significantly diminished humoral and cellular immune response 22 . Another study, that included 2 CAR-T recipients in a cohort of 20 cancer patients, confirmed profound immunosuppression and prolonged viral shedding and detected viable virus by cell culture 23 . Another study from Dana-Farber Cancer Institute examined outcomes in 127 cell therapy patients treated during the initial COVID-19 surge, including 27 CAR-T recipients. During the study period, 1 patient with DLBCL contracted COVID-19 fifty-one days after receiving tisa-cel and died due to COVID-19-related complications 121 days after CAR-T infusion 24 . Overview of B-cell development: The risk for infectious pathogens is likely associated with tumor-associated antigen (TAA) and the stage Additionally, BCMA is consistently expressed on malignant PCs with only limited distribution in normal tissue [32] [33] [34] [35] . Upregulation of BCMA also correlates with disease burden and prognosis in MM and is used as a target for anti-myeloma immune-engaging platforms 32, 36 . CD19 is expressed selectively on earlier stage B-cells and follicular DCs. CD19 plays a role in antigenindependent development and immunoglobulin activation of B-cells 37 An intricate balance of humoral and cell-mediated immunity protects against viral infections. Humoral immunity is provided by the B-cells that produce antibodies. The protective antibodies neutralize virus and prevent its entry into host cells. Protective immunity is rendered by neutralizing antibodies the potency and the concentration of which is quantified as the titer required to neutralize 50% of viral plaques in an immunoassay [50% inhibitory dilution (ID 50 ) ]. The neutralizing titers are then correlated with clinical outcomes 46 . For instance, a hemagglutination inhibition titer of 1:40 is thought to provide 50% protection from influenza infection 46 . Th2, orchestrate phagocytosis, cell-mediated immunity, and allergic-type inflammation. Antigen-specific memory B and T-cells persist and further provide memory to prevent future infections 48 . In a viral infection, the innate immune response is initiated by antigen-presenting cells, such as While there is a dearth of data related to COVID-19 outcomes among CAR-T recipients, there is greater Table 1 ) 2,10,53-62 . Additionally, CAR-T recipients are more like to be older (immunosenescence) with a suboptimal performance status, a higher comorbidity burden, and have likely received multiple lines of treatment prior to CAR-T receipt. VIII.1) Risk for infections with signaling domains, CD28 and 41BB: The two most employed signaling domains of costimulatory receptors in modern CAR-T constructs include CD28 and 4-1BB. CD28-based CAR-T cells elicit a robust initial proliferative response and yield effector memory T-cells, whereas 4-1BB co-stimulation induces a slower and progressive response and endow CAR-T with enhanced persistence and central memory differentiation [63] [64] [65] [66] . Theoretically, CD28based CAR-T constructs confer a higher risk or more frequent and severe CRS compared to 4-1BB-based CAR-T constructs. However, the toxicities need to be compared in head-to-head prospective analyses as varying CRS grading and treatment algorithms were utilized in the pivotal trials that led to the FDA approval of CD28 and 4-1BB-based CAR-T products. The data from pivotal clinical trials for FDAapproved CAR-T constructs are given in table 2. In vitro studies had demonstrated that cyclophosphamide (Cy)-based conditioning chemotherapy improved the efficacy and expansion of adoptively transferred tumor-infiltrating lymphocytes 67 VIII.3) CRS as a risk factor for infections: The FDA-approved second-generation CAR-T constructs primarily differ in their costimulatory domains (tisa-cel, liso-cel, and ide-cel [4-1BB based] and axi-cel and brex-cel [CD28 based] CARs) [4] [5] [6] [7] [8] [9] . This confers a differential risk of CRS, particularly severe CRS. The immune dysregulation associated with CRS has been linked to the risk of infections. While the exact mechanisms that incite and perpetuate CRS remain to be elucidated, the hyper-cytokinemia related to robust expansion of CAR T-cells may lead to immune paralysis, tissue damage, and disruption of the mucosal barrier [74] [75] [76] . The production of IL-6 is thought to be critical to the development of CRS. IL-6 signaling is positively correlated with the production of other proinflammatory cytokines and chemokines 76 . Additionally, IL-6 activates the differentiation of monocytes and macrophages, inhibits Tregs, and attracts other immune cells, potentially amplifying CRS 77, 78 . Further, severe CRS has been shown to delay neutrophil engraftment, which may predispose to infections 76, 79 . Coupled with the compounded use of immune modulators used for its treatment, such as corticosteroids and IL6-blockade, the immune dysregulation after severe CRS it may impact long-term responses to vaccines as well 60, [80] [81] [82] . CRS severity has been shown to be associated with an increased risk for infections in several studies. A study examining infection density and pre-and post-treatment risk factors for infection within the first 3 months among 133 CD19+CAR-T recipients showed that the infection density was higher in the first 30 days compared to later between days 29 and 90. Within the first 30 days, bacterial infections (23% patients) were the commonest, followed by viral (17% patients) and fungal infections (3%). While patients with ALL, greater prior lines of treatment, and a higher CAR T-cell dose associated with a higher infection density, CRS was the only risk factor that was independently associated with infections. Additionally, 46% patients had hypogammaglobulinemia (IgG < 400 mg/dL) by day 90 81 CRS developing after haploidentical cell transplantation (haploHCT) has also been associated with infections. In a single-center study including 78 consecutive adult haploHCT recipients, investigators showed that severe CRS developing after post-transplantation cyclophosphamide-based haploHCT was independently associated with an increased incidence of infections 79 . The development of severe CRS is associated with a significantly increased risk of NRM, likely driven by increased infections 84 . CAR T-cell therapy results in the depletion of normal CD19-bearing cells. The associated hypogammaglobulinemia can be considerably prolonged, predisposes to infections, and impacts outcomes of CAR-T recipients 5, 53, 54, 59, 60, 81, 85 . Furthermore, the durability and response rate to CAR-T correlates with B-cell aplasia. With increasingly sophisticated CAR-T constructs that harness multiple signaling domains and target more than one TAAs, prolonged B-cell aplasia is likely to be an unavoidable, long-term complication in CAR-T recipients for the foreseeable future 2, 4, 5, 7, 18, 86, 87 . However, the incidence and duration of hypogammaglobulinemia, as a function of TAA, and its impact on infections and survival and outcomes have not been examined systematically. CAR T-cell persistence results in delayed B-cell aplasia; hence, hypogammaglobulinemia may be more profound in patients with R/R B-cell ALL treated with tisa-cel than patients with R/R DLBCL who receive tisa-cel or axi-cel. Immunoglobulin G (IgG) starts to decrease as early as one month after CAR T-cell To that end, a small single-center study examined the impact of G-CSF in axi-cel recipients with R/R DLBCL. Seven patients (31.8%) received G-CSF upon physician discretion. While the median duration of neutropenia, after LD chemotherapy, was significantly shorter for patients who received G-CSF (5 vs. 15 days, P=0.016), there was no difference in the incidence and severity of infection based on G-CSF use. Interestingly, while there was no significant difference in the incidence of developing CRS or ICANS between the 2 groups, there was a significant increase in CRS severity for patients that received filgrastim compared to those that did not (P=0.042) 98 . In another single-center study examining 70 axi-cel and tisa-cel recipients with R/R DLBCL, 42 (60%) received prophylactic G-CSF and 28 (40%) did not receive G-CSF. While there was no difference between the 2 groups in terms of duration of neutropenia and infections, the patients in the G-CSF group were older (63 vs 50 years, P=0.002), and had lower neutrophil count at day+0 as well as at day+5. Most patients in the study experienced grades 1-2 CRS, and there was no difference between the 2 groups in terms of incidence and severity of CRS. Similarly, 30% of patients experienced ICANS with no significant difference between the 2 groups 99 . Overall, the role of recombinant G-CSF to aid neutrophil recovery in CAR-T setting remain unexplored. Larger studies comparing the efficacy, in preventing infections, and toxicity, in G-CSF potential to worsen the on-target-off-tumor CAR-T effects, in homogeneous patient cohorts are needed. The pivotal phase-II KarMMa trial examined the safety and efficacy of ide-cel (bb2121; Abecma), a 4-1BB-based CAR-T construct directed against BCMA in patients with RRMM that were previously treated with at least 3 prior therapies 8 infections associated with hypogammaglobulinemia and compromised humoral immunity [106] [107] [108] . Patients with MM are a particularly higher risk of bacterial and viral infections due to globally compromised immune system 109, 110 . These patients may be at a particularly higher risk for severe COVID-19 as well as suboptimal vaccine responses. The addition of monoclonal antibodies, immunomodulators, and small molecules to the backbone of frontline regimens further compounds the risk with distinctive infections. For instance, viral reactivations may occur following tyrosine kinase inhibitors, Janus kinase inhibitors, and monoclonal antibodies. Increased risk for pneumonia due to pneumocystis jirovecii with purine analogs, in vivo T-cell depletion agents, corticosteroids, and phosphatidylinositol 3-kinase inhibitors. Vaccine development against SARS-CoV-2 has employed several platforms, including inactivated, protein subunit, replication-incompetent viral vector-based, and nucleic acid-based 111 The Evolving data suggest that patients with HM may have a diminished immune response to the SARS-CoV-2 vaccine 121 . Underlying disease, overall state of immunosuppression, remission status, receipt of active treatment, and immune reconstitution profile may impact the response (Table 1) . Diminished In Immunocompromised patients are at a higher risk for the shedding of the replication-incompetent virus 52, 136 . Patients with HM undergoing active treatment, particularly B-cell depleting therapy such as CAR-T, are at a higher risk for prolonged viral shedding. Prolonged usage of corticosteroids has been shown to impact viral kinetics in a similar manner. The differential pattern of viral receptor expression and tropism in immunocompromised patients are reviewed elsewhere 52, 137 . Several reports have recently suggested that SARS-CoV-2 variants, with greater transmissibility and pathogenicity, can arise during such a protracted course of COVID-19 138, 139 . Multiple mutations result in the generation of clinical and public health concern variants. These mutations predominate in the spike protein as this is the prime target of the protective antibody response and mediates viral entry. Potential strategies to boost vaccine response in CAR-T recipients: Additional vaccine doses are likely needed in patients with profoundly suppressed humoral immunity and a high cumulative risk of severe infection (Table 1) . Early studies demonstrate the feasibility of CAR.λ and CAR.κ-T cells that will not lead to B-cell aplasia and, hence, hold potential for minimal impact on humoral immunity 140 . Meanwhile, the timing and intensity of corticosteroid usage, both for the prevention and treatment of CAR-T toxicities, should be reviewed given the potential for diminished immune responses 141 . Growing evidence related to the heterologous prime-boost with alternate vaccine technologies is also promising 142, 143 . Initial studies have shown that sequential immunization with adenovirus vectored vaccine and inactivated, recombinant subunit, and mRNA vaccine administration results in higher levels of neutralizing antibodies, more potent humoral immune responses, and T-cell reactivity 144 . However, longitudinal studies are needed to determine optimal sequence, vaccine platform, and timing to establish safety and reduce vaccine-associated reactogenicity in profoundly immunosuppressed CAR-T recipients. Evidence from the SARS-CoV-1 epidemic had previously shown significantly greater durability with memory T-cell response compared to antibodies 48 . The results of prospective mechanistic studies such as CIBMTR study SC21-07/BMT-CTN 2101 are keenly awaited 47, [145] [146] [147] [148] . Further, long-acting monoclonal antibodies or small molecules potentially resistant to current SARS-CoV-2 mutations will need evaluation in prospective studies in cellular therapy recipients. Additionally, halting active viral replication with antiviral agents to prevent the development of mutations also remains an unmet need. Immunity to SARS-CoV-2 is conferred by intricate crosstalk of both antibody and T-cell responses. Insight into both responses is needed for an optimal understanding of protection in this vulnerable patient group. Longitudinal serological and cellular studies are essential to understand the duration of immunity and addressing whether revaccination or boosting would be required and if this is contingent upon the TAA that the CAR is designed to target. Telemedicine should be incorporated at the core of long term follow up to minimize exposure of immunosuppressed patients to the hospitals and the community. Until the data become available, the risk of nosocomial transmission should be minimized by vaccinating all healthcare workers caring for patients with HM, and strict mitigation strategies should remain across cancer centers. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Disclosures: None of the authors have any financial disclosures or conflicts of interest related to this manuscript. Abbreviations: CAR-T, chimeric antigen receptor T-cells; ALL, acute lymphoblastic leukemia; R/R, relapsed/refractory; DLBCL, diffuse large B-cell lymphoma; NHL, Non-Hodgkin's lymphoma; MM, multiple myeloma; MCL, mantle cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; BCMA, Bcell maturation antigen; CR, complete response; stringent CR; PFS, progression-free survival; NR, not reported; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; FL, follicular lymphoma; PBMC, peripheral blood mononuclear cells; LD, lymphodepletion; Flu, fludarabine; Cy, cyclophosphamide; B, bendamustine. Chimeric Antigen Receptor Therapy Gut microbiome and CAR-T therapy The Promise and Challenges of CAR-T Gene Therapy Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Shah Net al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation COVID-19 outcomes in patients with hematologic disease Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study Risk factors and outcome of COVID-19 in patients with hematological malignancies Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience The chemokine CXCL12 and regulation of HSC and B lymphocyte development in the bone marrow niche Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A Gene segment selection in V(D)J recombination: accessibility and beyond Transitional B cells: step by step towards immune competence BAFF selectively enhances the survival of plasmablasts generated from human memory B cells BCMA is essential for the survival of long-lived bone marrow plasma cells B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses Pittaluga Set al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma A molecular compendium of genes expressed in multiple myeloma Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment Targeting B-cell maturation antigen in multiple myeloma Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes An antibody-deficiency syndrome due to mutations in the CD19 gene CD19: a promising B cell target for rheumatoid arthritis Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules Enforced CD19 Expression Leads to Growth Inhibition and Reduced Tumorigenicity A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses Vogler Iet al. BNT162b2 vaccine induces neutralizing antibodies and polyspecific T cells in humans Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia Hypogammaglobulinemia due to CAR T-cell therapy How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB The revving up of CARs Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells CAR-T efficacy: is conditioning the key? Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation Current concepts in the diagnosis and management of cytokine release syndrome Cytokine release syndrome CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma Infectious complications of CD19-targeted chimeric antigen receptormodified T-cell immunotherapy Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Early and late hematologic toxicity following CD19 CAR-T cells Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts Granulocyte-macrophage colonystimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update Filgrastim associations with CAR T-cell therapy G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients Immunodeficiency and immunotherapy in multiple myeloma SARS-CoV-2 vaccines in development A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel) Kitchin Net al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents Kitchin Net al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants Falsey ARet al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Neutralizing Activity of BNT162b2-Elicited Serum Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations IDSA clinical practice guideline for vaccination of the immunocompromised host Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia Interim results of the safety and immuneefficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group Hemophagocytic lymphohistiocytosis after COVID-19 vaccination Kawasaki like illness due to COVID-19: a review of the literature SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia Gernsheimer Tet al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer Bronchoalveolar lavage-based COVID-19 testing in patients with cancer Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host SARS-CoV-2 evolution during treatment of chronic infection CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Dexamethasone premedication suppresses vaccine-induced immune responses against cancer Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. The Lancet Respiratory medicine Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates Heterologous vaccination regimens with selfamplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity Prolonged B-cell aplasia, hypogammaglobulinemia, and cytopenia predispose CAR-T recipients to severe infections. The risk of infections and humoral and cellular response to SARS-CoV-2 vaccine with CAR-T depends upon several patient-and disease-related factors. These include lymphodepletion chemotherapy regimen, the interval between cell collection and infusion, bridging therapy, CAR T-cell dose, signaling and costimulatory domains, target antigen (CD19 versus BCMA, etc.), and duration of lymphopenia and hypogammaglobulinemia. CD28-based CAR-T constructs confer a higher risk or more frequent and severe CRS compared to 4-1BB-based CAR-T constructs and hence a higher incidence for infections Table 1: Patient, disease, and CAR-T related factors potentially associated with the risk of infections * References Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults Infectious complications of CD19-targeted chimeric antigen receptormodified T-cell immunotherapy Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Early and late hematologic toxicity following CD19 CAR-T cells Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies Racial disparities in hematopoietic cell transplantation in the United States Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes Obesity and cancer immunotherapy toxicity Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells Fludarabine and neurotoxicity in engineered T-cell therapy Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs CAR-T efficacy: is conditioning the key? Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL Clin Infect Dis 2021. 28. van Zelm MC, Reisli I, van der Burg Met al. An antibody-deficiency syndrome due to mutations in the CD19 gene Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma Dexamethasone premedication suppresses vaccine-induced immune responses against cancer Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Shah Net al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study As of this writing, the U.S. FDA has granted priority review to the biologics license application for ciltacabtagene autoleucel (cilta-cel) Corticosteroid and tocilizumab utilization increased with increasing CAR T-cell dose Current concepts in the diagnosis and management of cytokine release syndrome Blood 2014) and ICANS by CTCAE, v5.0 (in phase 1b). CRS and ICANS were graded by ASTCT criteria Abbreviations: CAR-T, chimeric antigen receptor T-cells; CNS, central nervous system; HCT, hematopoietic cell transplantation; ALL, acute lymphoblastic leukemia; MRD, measurable residual disease; B-NHL, B-cell non-Hodgkin's lymphoma; LDH, lactate dehydrogenase; LD, lymphodepletion; MM, multiple myeloma; ISS, international staging system; IgM, immunoglobulin M; PI, proteasome inhibitor; IMiD, immunomodulatory agent; mAb; monoclonal antibody; SINE, selective inhibitor of nuclear export; BMI, body mass index; KPS, karnofsky performance score, HCT-CI, hematopoietic cell transplantation comorbidity index; FluCy, fludarabine and cyclophosphamide; HaploHCT, haploidentical HCT; BCMA, B-cell maturation antigen; CRS, cytokine release syndrome. *Variables that have been shown to independently impact the risk of infection in CAR-T setting are referenced. The remaining factors are extrapolated from the allogeneic HCT data.